NTLA
Intellia Therapeutics Inc

14,348
Mkt Cap
$1.65B
Volume
3.25M
52W High
$28.25
52W Low
$5.90
PE Ratio
-3.35
NTLA Fundamentals
Price
$13.78
Prev Close
$14.28
Open
$13.84
50D MA
$11.66
Beta
1.71
Avg. Volume
6.9M
EPS (Annual)
-$5.25
P/B
2.21
Rev/Employee
$143,615.39
$761.26
Loading...
Loading...
News
all
press releases
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.
Zacks·14h ago
News Placeholder
More News
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Given "Buy" Rating at Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $26.00 price objective on shares of Intellia Therapeutics in a report on Friday...
MarketBeat·15h ago
News Placeholder
Brookline Capital Acquisition Weighs in on NTLA Q1 Earnings
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Investment analysts at Brookline Capital Acquisition issued their Q1 2026 EPS estimates for shares of Intellia Therapeutics in a report...
MarketBeat·18h ago
News Placeholder
Intellia Therapeutics Q4 Earnings Call Highlights
Intellia Therapeutics (NASDAQ:NTLA) management used its fourth-quarter and full-year 2025 earnings call to highlight progress across its two lead in vivo CRISPR gene-editing programs lonvo-z in...
MarketBeat·1d ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Expectations By $0.16 EPS
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus...
MarketBeat·1d ago
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +15.82% and +94.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Earnings Preview For Intellia Therapeutics
read more...
Benzinga·2d ago
News Placeholder
ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of +25.00% and +3.19%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
What's in Store for These 5 Medical Companies This Earnings Season?
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Zacks·5d ago
News Placeholder
Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus
NTLA, CL and GTY are in focus as Zacks highlights strong 12-week gains and post-upgrade rallies across its Focus List and model portfolios.
Zacks·5d ago
<
1
2
...
>

Latest NTLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.